Article

Lower birthweight criterion suggested for ROP screenings

A birthweight of 1,250 g may be a dependable criterion for screening for retinopathy of prematurity (ROP) and also might reduce the number of examinations, suggested Shailesh K. Gupta, MD, University of Florida College of Medicine, Jacksonville. Current guidelines recommend screening of infants under 1,500 g or a gestational age of less than 28 weeks.

Chicago-A birthweight of 1,250 g may be a dependable criterion for screening for retinopathy of prematurity (ROP) and also might reduce the number of examinations, suggested Shailesh K. Gupta, MD, University of Florida College of Medicine, Jacksonville. Current guidelines recommend screening of infants under 1,500 g or a gestational age of less than 28 weeks.

Dr. Gupta based this conclusion on a retrospective study of 208 infants screened for ROP over a period of 2 years at a large academic medical center. The infants were divided into group 1 (n = 158), whose birthweight was less than or equal to 1,250 g, and group 2 (n = 50), whose birthweight was more than 1,250 g. The mean gestational age of infants in group 1 was 26.8 weeks; it was 30 weeks in group 2. Investigators found 116 eyes with ROP in group 1 and one case in one eye in group 2.

They analyzed numerous factors, including the maximum stage of ROP, and calculated sensitivity, specificity, and positive predictive value.

“The advantage of decreasing screening criteria to 1,250 g is that it increases the efficiency of ROP screenings. In our data set, it decreased screenings by 24% and decreased the expense,” Dr. Gupta said. He noted that multicenter studies of this hypothesis are needed and that future analyses need to take into account the racial and ethnic backgrounds of the infants.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.